Duopharma Biotech Financials
| 7148 Stock | 1.24 0.01 0.81% |
Duopharma |
Understanding current and past Duopharma Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Duopharma Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Duopharma Biotech's assets may result in an increase in income on the income statement.
| Instrument | Malaysia Stock View All |
| Exchange | Kuala Lumpur Exchange |
| ISIN | MYL7148OO009 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Benchmark | Dow Jones Industrial |
You should never invest in Duopharma Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Duopharma Stock, because this is throwing your money away. Analyzing the key information contained in Duopharma Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Duopharma Biotech Key Financial Ratios
There are many critical financial ratios that Duopharma Biotech's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Duopharma Biotech Bhd reports annually and quarterly.Duopharma Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Duopharma Biotech's current stock value. Our valuation model uses many indicators to compare Duopharma Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Duopharma Biotech competition to find correlations between indicators driving Duopharma Biotech's intrinsic value. More Info.Duopharma Biotech Bhd is number one stock in return on equity category among its peers. It also is the top company in current valuation category among its peers reporting about 162,703,409 of Current Valuation per Return On Equity. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Duopharma Biotech's earnings, one of the primary drivers of an investment's value.Duopharma Biotech Bhd Systematic Risk
Duopharma Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Duopharma Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Duopharma Biotech Bhd correlated with the market. If Beta is less than 0 Duopharma Biotech generally moves in the opposite direction as compared to the market. If Duopharma Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Duopharma Biotech Bhd is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Duopharma Biotech is generally in the same direction as the market. If Beta > 1 Duopharma Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Duopharma Biotech Thematic Clasifications
Duopharma Biotech Bhd is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
Duopharma Biotech December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Duopharma Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Duopharma Biotech Bhd. We use our internally-developed statistical techniques to arrive at the intrinsic value of Duopharma Biotech Bhd based on widely used predictive technical indicators. In general, we focus on analyzing Duopharma Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Duopharma Biotech's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.91 | |||
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 9.73 | |||
| Value At Risk | (2.52) | |||
| Potential Upside | 2.56 |
Other Information on Investing in Duopharma Stock
Duopharma Biotech financial ratios help investors to determine whether Duopharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Duopharma with respect to the benefits of owning Duopharma Biotech security.